Vibrio cholerae O1 Variant with Reduced Susceptibility to Ciprofloxacin, Western Africa by Quilici, Marie-Laure et al.
LETTERS
likely acquired when animals were 
housed in enclosures previously oc-
cupied by infected raccoons or when 
bedding or food became contaminated 
with  B. procyonis–infected raccoon 
feces. In B. procyonis–endemic areas, 
cages used to house raccoons should 
be thoroughly decontaminated by 
ﬂ  aming, or cages should be dedicated 
for use by raccoons. Because B. pro-
cyonis roundworms can spread to other 
animals, persons in contact with rac-
coons should be alert to potential trans-
mission routes and apply appropriate 
biosecurity procedures.
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Ciproﬂ  oxacin, 
Western Africa 
To the Editor: Many variants of 
choleragenic vibrios have emerged 
since the beginning of the seventh 
pandemic, indicating continuous evo-
lution of this pathogenic agent. Varia-
tions occur mainly in genetic determi-
nants of virulence and antimicrobial 
drug susceptibility. In September–Oc-
tober 2009, concurrent outbreaks of 
acute watery diarrhea in northeastern 
Nigeria (4,559 cases) and northern 
Cameroon (696 cases) were inves-
tigated by state ministries of health. 
We report reduced sensitivity to cipro-
ﬂ  oxacin in Vibrio cholerae O1 strains 
and the atypical cholera toxin B (ctxB) 
genotype of these strains.
In September–October 2009, 
stool specimens from patients in Ni-
geria were collected on ﬁ  lter  paper, 
moistened with sterile physiologic 
saline, and sent at room temperature 
to the National Reference Center for 
Vibrios and Cholera at the Institut Pas-
teur (Paris, France). Ten V. cholerae 
O1 biotype El Tor serotype Ogawa 
strains were isolated and identiﬁ  ed 
by using standard procedures. Con-
currently in Cameroon, 9 V. cholerae 
O1 Ogawa strains isolated from pa-
tient stool samples by the bacteriol-
ogy laboratory of the Pasteur Center 
(Garoua, Cameroon) were sent to the 
National Reference Center for Vibrios 
and Cholera.
All strains were tested for antimi-
crobial susceptibility by MIC determi-
nation to tetracycline, trimethoprim/
sulfamethoxazole, sulfonamides, am-
picillin, chloramphenicol, nalidixic 
acid, and ciproﬂ  oxacin by using Etest 
(AB bioMérieux, Solna, Sweden) ac-
cording to Clinical and Laboratory 
Standards Institute procedures and in-
terpretative standards for V. cholerae 
(1). PCR ampliﬁ  cation of the genes 
encoding DNA gyrase (gyrA  and 
gyrB) and topoisomerase IV (parC 
and parE) and subsequent sequencing 
of PCR products were performed (2).
PCR was used to test for the pres-
ence of ctxA and ctxB genes, which 
encode the cholera toxin (CT), and the 
tcpA gene, which encodes the toxin-
coregulated pilus. Genotyping of ctxB 
was performed by sequencing PCR 
products.
All isolates showed susceptibility 
to tetracycline (MIC 1.5 mg/L), inter-
mediate susceptibility to ampicillin 
(MICs 12–16 mg/L) and chloramphen-
icol (MICs 8–12 mg/L), and resistance 
to trimethoprim/sulfamethoxazole 
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(MIC >32 mg/L), sulfonamides (MIC 
>1,024 mg/L), and nalidixic acid (MIC 
>256 mg/L). MICs of ciproﬂ  oxacin 
ranged from 0.25 to 0.5 mg/L.
Sequencing of gyrA, gyrB, parC, 
and parE genes among all strains de-
tected 1 mutation in gyrA (substitution 
of serine by isoleucine at position 83) 
and 1 mutation in parC (substitution 
of serine by leucine at position 85). 
Both point mutations have been as-
sociated with quinolone resistance 
in clinical isolates of V. cholerae (2). 
None of the strains had any mutations 
in gyrB or parE.
The presence of ctxA and ctxB 
genes conﬁ   rmed the toxigenicity of 
all isolates, and tcpA PCR product 
size and sequence identiﬁ  ed  El  Tor 
biotype strains. The DNA sequence of 
ctxB was similar to that of the recently 
reported Orissa variant identiﬁ  ed  in 
India in 2007 (3). This sequence had 
2 mutations resulting in histidine at 
position 39 and threonine at position 
68 (this amino acid sequence is similar 
to the CT-B subunit of the reference 
classical strain) and a third mutation 
resulting in substitution of histidine 
by asparagine at position 20.
We report atypical El Tor strains of 
V. cholerae O1 and their reduced sus-
ceptibility to ciproﬂ  oxacin in Nigeria 
and Cameroon. Since the 1990s, atypi-
cal El Tor strains that  produce classi-
cal CT have been increasingly report-
ed from countries in Asia, where they 
have gradually replaced the prototype 
El Tor strains, but they have only been 
reported in 2 countries in Africa (Mo-
zambique and Zambia) (4,5). On the 
basis of the CT-B subunit sequence, 
these variants differ from variants 
isolated in southern Africa and from 
most variants isolated in Asia by hav-
ing the same modiﬁ  ed classical CT as 
a strain recently isolated in Orissa in 
eastern India (3), which has not been 
reported elsewhere. These ﬁ  ndings in-
dicate evolution of V. cholerae O1 El 
Tor hybrid strains. Their presence may 
indicate spread of strains from eastern 
India to Africa (6).
 The presence of CT-B variants 
in central or western Africa is of great 
concern because these strains may 
be more toxigenic (3). There is also 
concern for the strains isolated in this 
study because of their reduced suscep-
tibility to ciproﬂ  oxacin. Although re-
duced susceptibility to ﬂ  uoroquinolo-
ne is common in southern Asia (7,8), 
it was reported in Africa (Zimbabwe) 
only recently (9). Our ﬁ  ndings, in ad-
dition to the report of Islam et al. (9), 
indicate that V. cholera with reduced 
sensitivity to a ﬂ  uoroquinolone  is 
present in southern and western Afri-
ca. These results highlight the need for 
continued monitoring of antimicrobial 
drug susceptibility and strain tracking 
to maintain an efﬁ  cient cholera sur-
veillance system.
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